5Madden TD,Demir AS,Redelmeier TE,et al.Encapsulation of camptothecin class topo- isomerase I inhibitors in lipid- based carrier systems.Evaluation of drug stability and plasma elimination in a murine model,and comparison of antitumor efficacy against muri
6Bom D,Curran DP,Zhang J,et al.The highly lipophilic DNA topoisomerase I inhibitor DB -67 displays elevated lactone levels in human blood and potent anticancer activity [ J ].J Control Release,2001,74 (3): 325 - 333.
8Subramanian D,Muller MT.Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan [J].Oncol Res,1995,7 (9):461 - 469.
9Burke TG,Gao X.Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine [ J ].J Pharm Sci,1994,83 (7): 967 - 969.
10Yasuyuki Sadzuka,Sachiyo Hirotsu,Sadao Hirota.Effect of liposomalization on the antitumor activity,side - effects and tissue distribution of CPT - 11[J].Cancer Letters,1998,127 ( 1 - 2): 99 - 106.
6[1]Handjani-Vila RM, Ribier A, Rondot B, et al. Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmet Sci [J], 1979,1(5):303-314.
7[2]Baillie AJ, Florence AT, Hume LR, et al. The preparation and properties of niosomes-non-ionic surfactant vesicles. J Pharm Pharmacol [J], 1985,37(12):863-868.
8[3]Namdeo A, Jain NK. Niosomes as drug carriers. Indian J Pharm Sci [J], 1996,58(2):41-46.
9[4]Andersson M, Hammarstrom L, Edwards K. Effect of bilayer phase transitions on vesicle structure and its influence on the kinetics of viologen reduction. J Phys Chem [J], 1995,99(39):14531-14538.
10[5]Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst [J], 1993,85(4):271-291.
